Published on 10/24/2016 in the Prospect News Structured Products Daily.
New Issue: UBS prices $175,000 return optimization securities on iShares Nasdaq Biotech
New York, Oct. 24 – UBS AG, London Branch priced $175,000 of return optimization securities due Oct. 31, 2017 linked to the shares of iShares Nasdaq Biotechnology ETF, according to a 424B2 filing with the Securities and Exchange Commission.
If iShares Nasdaq Biotech shares close at or above the initial price, the payout at maturity will be par plus two times any gain in shares of iShares Nasdaq capped at 22.57%.
Investors will share in any losses.
UBS Financial Services Inc. and UBS Investment Bank are the underwriters.
Issuer: | UBS AG, London Branch
|
Issue: | Return optimization securities
|
Underlying ETF: | iShares Nasdaq Biotechnology ETF
|
Amount: | $175,000
|
Maturity: | Oct. 31, 2017
|
Coupon: | 0%
|
Price: | Par of $10
|
Payout at maturity: | Par plus two times any gain in shares of iShares Nasdaq, capped at 22.57%; otherwise, exposure to any losses
|
Initial share price: | $266.41
|
Pricing date: | Oct. 24
|
Settlement date: | Oct. 27
|
Underwriters: | UBS Financial Services Inc. and UBS Investment Bank
|
Fees: | 1%
|
Cusip: | 90280F603
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.